Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

725.96
-16.1600-2.18%
Volume:152.19K
Turnover:111.02M
Market Cap:74.74B
PE:17.95
High:744.50
Open:742.12
Low:723.65
Close:742.12
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.55
T/O Rate:0.15%
Dividend:3.64
Dividend Rate:0.50%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.36
PE(LYR):17.50

Loading ...

Regeneron Pharma Price Target Raised to $779.00/Share from $758.00 by Morgan Stanley

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758

MT Newswires Live
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing

THOMSON REUTERS
·
Oct 06

Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing

THOMSON REUTERS
·
Oct 06

Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026

Reuters
·
Oct 06

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating

MT Newswires Live
·
Oct 06

Sanofi Can Move Forward to Pursue Deals

Dow Jones
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Oct 06

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating

MT Newswires Live
·
Oct 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Oct 02

Piper Sandler Remains a Buy on Regeneron (REGN)

TIPRANKS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02